Previous slide arrow

EMA grants positive CHMP opinion for KYGEVVI® for Treatment of TK2d

IMP are celebrating an important regulatory milestone in Europe: the European Medicines Agency’s (EMA) has adopted a positive opinion recommending KYGEVVI® (doxecitine and doxribtimine) for the treatment of adults and children living with Thymidine Kinase 2 Deficiency (TK2d), with an age of symptom onset on or before 12 years.

Illustration of a cell against a dark background with the mitochondria lit up in orange

Thank You for Supporting Mito Week 2025

Your participation has helped shine a light on mitochondrial disease and strengthen the call for awareness, research, and support. Let’s keep raising awareness together and continue driving change beyond this week. We’re already looking forward to building on this momentum for next year’s campaign.

TK2D Awareness Day – 9 September 2025

Watch Lisa, Aneesa and Viviane tell their stories of living with K2d (thymidine kinase 2 deficiency), diagnosis, the heartbreak of loss, and the hope brought by clinical trials and community support.

Image of a mother with long blonde dreadlocks holding a child with short black hair on her lap who is attached to a breathing machine

LHON Awareness Day – 19 September 2025

Watch our webinar on nutrition and mitochondrial diseases with a special focus on LHON.

Title slide of a presentation showing the title 'Exploring the Power of Nutrition in Mitochondrial Diseases'
r


Mitochondrial diseases (mito) are a highly complex set of rare genetic disorders. Mito can cause any symptom in any organ at any age. They rob the body’s cells of energy causing debilitating and often life-threatening organ dysfunction.

About
MITO

NEWS

EMA grants positive CHMP opinion for KYGEVVI® for Treatment of TK2d

EMA grants positive CHMP opinion for Kygevvi® for Treatment of TK2d International Mito Patients (IMP) and the global mitochondrial disease community […]...

Funding for the SynLeigh Project to Advance New Therapies for Leigh Syndrome

Funding for the SynLeigh Project to Advance New Therapies for Leigh Syndrome IMP, Mitocon and Cure Mito Welcome ERDERA Funding International […]...

IMP Annual Meeting 30-31 May 2026, France

IMP Annual Meeting 30-31 May 2026, France IMP’s Annual Meeting will take place 30–31 May 2026 at Brit Hotel Acropole, […]...

Patients at the Heart of Research: IMP’s Role in the SIMPATHIC Drug Repurposing Project

Patients at the Heart of Research: IMP’s Role in the SIMPATHIC Drug Repurposing Project The SIMPATHIC project continues to make […]...

Amplifying Our Collective Voice: IMP at National and International Events

Amplifying Our Collective Voice: IMP at National and International Events As members of IMP, we are part of a global […]...

Meet
a member

The POLG Foundation

The PolG Foundation is committed to accelerating research efforts to develop effective treatments and, ultimately, a cure for POLG mitochondrial disorders.


Become
a member

Are you thinking of becoming an IMP member?

Patient Stories

Ellie was a fighter from birth. Born in October 2017, a lack of oxygen at birth meant she needed to spend the first week of life in intensive care. This early battle in life would later be a blessing in disguise as it meant she required regular neurological reviews to review how her brain and movement developed. Ellie’s early months were mainly happy. She cried, babbled and smiled like any baby does and loved baths with her big sister, kicking her legs to music and chatting away with her mum and dad.

About
IMP

International Mito Patients is a non-profit network of national patient organisations involved in mito. The national patient organisations support and advocate for patients, fund research, increase awareness and improve education in their country.

By joining forces, IMP represents a large group of patients, creating a stronger voice on an international level.

IMP’s mission is to increase the quality of life for people with mitochondrial disease by facilitating cross-border cooperation and collaboration among national patient organisations.


Stay up
to date

Translate
Scroll to Top